Alternative Approaches to Treating Antimicrobial Resistant Infections, 3rd Edition

Guest Editors:

**Dr. Michal Letek**
Department of Molecular Biology, Area of Microbiology, Universidad de León, 24071 Leon, Spain

**Dr. Volker Behrends**
Department of Life Sciences, University of Roehampton, London, UK

Deadline for manuscript submissions: 31 January 2025

**Message from the Guest Editors**

This Special Issue will focus on alternative approaches to treating antimicrobial-resistant infections. The discovery of antibiotics revolutionized the clinical treatment of bacterial infections; as a consequence, many infections are now difficult to treat, which is raising mortality and healthcare-associated costs due to difficulties in accomplishing total remission. Antimicrobial resistance is now considered to be one of the greatest risks to humanity. Common surgical procedures and treatments that could lead to immunosuppression may soon be considered high-risk due to the antibiotic crisis.

We are therefore inviting both reviews and original articles on the latest developments in novel antibacterial strategies with which to treat infections caused by antimicrobial-resistant pathogens. Topics include the development of novel combinatorial therapies based on the repurposing of anti-infectives, host-targeted therapies, bacteriophages, the use of predatory bacteria, bacteriocins, antimicrobial peptides, nanoparticles, natural compounds, immunotherapeutics, probiotics used for the competitive exclusion of pathogens, and the development of novel antibacterial compounds.
Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics )

Contact Us

Antibiotics Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
@antibioticsmdpi